Document Detail

Myocardial tissue engineering and heart muscle repair.
MedLine Citation:
PMID:  23092254     Owner:  NLM     Status:  MEDLINE    
Cardiovascular diseases, including myocardial infarction and heart failure, are the main causes of death worldwide. Classical pharmacological treatment may halt, but cannot reverse the underlying disease process. Cellular cardiomyoplasty has the potential to reconstruct myocardium in situ; yet, it is hampered by poor cell survival, engraftment, and differentiation. Tissue engineering has emerged as an alternative cell-based approach, aiming at partial or full replacement of damaged organs with in vitro generated tissue equivalents. However, limited availability of therapeutic cardiomyocytes poses a major challenge on cell-based and in particular tissue engineering-based therapies. Rapidly evolving stem cell technologies, enabling mass cultures may overcome this limitation. Translating available experimental concepts into clinical reality will be the ultimate challenge. This review discusses potentially therapeutic cells for cardiac repair, current stem cell-based myocardial tissue engineering strategies, and the requirements for a translation of myocardial tissue engineering into clinical practice.
Bijoy Chandapillai Karikkineth; Wolfram-Hubertus Zimmermann
Related Documents :
6824544 - Transience of left ventricular thrombosis.
2387544 - Coronary embolism by metastatic choriocarcinoma of the uterus: an unusual cause of isch...
9426014 - Does intracoronary thrombus influence the outcome of high risk percutaneous translumina...
933364 - A case of tumor embolism of the coronary artery, resulting in myocardial infarction and...
9129244 - Enhancement of coronary reactive hyperemia in patients with ischemic myocardial toleran...
10749694 - Effect of 6-wk estrogen withdrawal or replacement on myocardial ischemic tolerance in r...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  14     ISSN:  1873-4316     ISO Abbreviation:  Curr Pharm Biotechnol     Publication Date:  2013  
Date Detail:
Created Date:  2013-02-26     Completed Date:  2013-08-09     Revised Date:  2014-09-29    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  4-11     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Heart Diseases / therapy*
Myocardium / cytology*
Stem Cell Transplantation*
Tissue Engineering*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The 'other' in patterns of drinking: a qualitative study of attitudes towards alcohol use among prof...
Next Document:  Stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart diseas...